See what’s new.
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.
Duke, UNC, and NC State academics get crash course in building startups
Faculty and students with promising IP developed at Triangle universities were invited to workshop their ideas with the help of serial entrepreneurs.
How old are you, really? Biological aging tech from Duke inventors spotlighted on TV
Professors Terrie Moffitt and Avshalom Caspi (Psychology & Neuroscience, Trinity) are leading experts in biological aging and have invented a test that is now a commercial product.
Seeds of Hope – Duke Magazine
Dr. Darell Bigner journeys from the farm to the heights of neuro-oncology and back again
Greenlight Health Data Solutions and Pattern Health Merge to Expand Healthcare, Life Sciences and Insurance Solutions
Pattern Health has licensed numerous technologies from Duke inventors, primarily clinical trial management software and supporting materials from the Duke University School of Medicine.
NSF-Piedmont Triad Regenerative Medicine Engine (PTRME) Awards $2.5 Million in Grants to Drive Economic Growth
BMI OrganBank licensed perfusion tech from the Duke Ex-Vivo Organ Lab, led by Drs. Andrew S. Barbas and Matthew Hartwig (Surgery, SOM).
Invented at Duke 2024 showcases the past and present of innovation at Duke, promising a bright future
A special Centennial edition of Invented at Duke featured inventors and innovations from the past, present, and future of Duke.
BMI OrganBank Secures $3.5 Million NIH Grant to Advance Innovative Kidney Preservation Technology Towards Clinical Trials
BMI OrganBank licensed perfusion tech from the Duke Ex-Vivo Organ Lab, led by Drs. Andrew S. Barbas and Matthew Hartwig (Surgery, SOM).
DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform to Characterize Drug Effects and Optimize Neurological Care
DANNCE.ai, a start-up from the lab of Assistant Professor Timothy Dunn (BME, Pratt), is also in the Duke Capital Partners portfolio.